Alrizomadlin
As of the edition of 20 October 2026, Alrizomadlin is a small molecule: in active development; acts on MDM2 and TP53.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 9, 1 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Inherited and neonatal; Lungs and airways; Mouth and teeth
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 1 | 0 |
| Phase 2 | 7 | 0 | 5 | 1 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Ascentage Pharma | Lead sponsor of trials | 2016 to now |